

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, DC 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2010**

---

**Commission File Number: 00 1 -32371**

---

**SINOVAC BIOTECH LTD.**

**No. 39 Shangdi Xi Road  
Haidian District  
Beijing 100085, People's Republic of China**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SINOVAC BIOTECH LTD.

By: /s/ Weidong Yin

Name: Weidong Yin

Title: Chairman and Chief Executive Officer

Date: June 21, 2010

## Exhibit Index

Exhibit 99.1 – Press Release

Exhibit 99.2 – Notice of 2010 Annual General Meeting of Shareholders

Exhibit 99.3 – Proxy Card

**Sinovac Schedules 2010 Annual Meeting of Shareholders**

Beijing — June 18, 2010 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of May 26, 2010 will be eligible to vote and are invited to attend. Sinovac 2009 annual report and the proxy statements are also be available on the company's website:

<http://www.sinovac.com/Investors/SECFilings/>  
<http://www.sinovac.com/Investors/IRHome/presentation/>.

**About Sinovac**

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), and Anflu® (influenza). Panflu™, Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

For more information, please contact:

Chris Lee  
Sinovac Biotech Ltd.  
Tel: +86-10-8279-9659  
Fax: +86-10-6296-6910  
Email: [lill@sinovac.com](mailto:lill@sinovac.com)

Investors:  
Amy Glynn/Stephanie Carrington  
The Ruth Group  
Tel: +1-646-536-7023/7017  
Email: [aglynn@theruthgroup.com](mailto:aglynn@theruthgroup.com)  
[scarrington@theruthgroup.com](mailto:scarrington@theruthgroup.com)

Media:  
Jason Rando  
The Ruth Group  
Tel: +1-646-536-7025  
Email: [jrando@theruthgroup.com](mailto:jrando@theruthgroup.com)

---



June 1 , 20 10

Dear Shareholder:

You are cordially invited to attend the 20 10 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on July 15, 2010 , at 9 : 00 A .M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in Antigua at No. 6 Temple Street, St. John’s, Antigua.

At this year’s annual meeting you will be asked to:

- approve the re-election of Weidong Yin, Xianping Wang, Yuk Lam Lo, Simon Anderson and Chup Hung Mok as the Company’s directors until the next annual meeting of shareholders and until their successors are duly elected;
- approve the audited consolidated financial statements of the Company for the financial year ended December 31, 200 9 together with the Report of Independent Registered Public Accounting Firm thereon and the notes thereto;
- approve the appointment of Ernst & Young LLP as the independent auditor of the Company for the fiscal year ending December 31, 20 10 and to authorize the directors of the Company to fix such independent auditor’s remuneration;
- approve amendments to definitions and Section 7.8 of the Company’s by-laws in order to adopt the definitions used in the International Business Corporations Act of Antigua for “special resolutions” and “ordinary resolutions;”
- approve the amendment to Section 7.5 of the Company’s by-laws in order to lower the quorum of shareholders’ meetings from 50% to 33 1/3 % of common shares outstanding,
- approve the amendment to Section 13 of the Company’s by-laws in order to change the resolutions required to amend the Company’s by-laws to be based on a two-third majority of votes cast, rather than a majority of shares entitled to vote; and

The annual meeting will also transact such other businesses as properly may be brought before it or any adjournment thereof.

The accompanying Notice of Meeting and Proxy Statement describes these matters. We urge you to read this information carefully.

Your board of directors unanimously believes that re- election of its nominees for directors, the appointment of an independent auditor and authorization to fix such independent auditor’s remuneration, and the amendments to the by-laws are in the best interests of the Company and its shareholders, and, accordingly, recommends a vote “FOR” the re-election of all of the above directors, “FOR” the approval of the audited consolidated financial statements of the Company and Report of Independent Registered Public Accounting Firm thereon, “FOR” the appointment of Ernst & Young LLP as our independent auditor, and “FOR” all the amendments to our by-laws.

In addition to the business to be transacted as described above, management will speak on our developments in the past year and respond to comments and questions of general interest to shareholders.

---

It is important that your shares be represented and voted whether or not you plan to attend the annual meeting in person. You may vote by completing and mailing the enclosed proxy card or the voting instruction form provided by your broker or other nominee. This will ensure your shares are represented at the annual meeting.

Sincerely,

**SINOVAC BIOTECH LTD.**

/s/ Weidong Yin

---

Weidong Yin  
Chairman, Chief Executive Officer and Secretary

---

## TABLE OF CONTENTS

	<u>Page</u>
NOTICE OF 2010 ANNUAL MEETING OF SHAREHOLDERS	1
INFORMATION CONCERNING VOTING AND SOLICITATION	3
General	3
Who Can Vote	3
Voting by Proxy	3
Voting in Person	3
Revocation of Proxy	4
Quorum and Votes Required	4
Solicitation of Proxies	5
Assistance	5
Important Information About Us	5
ITEM 1: RE-ELECTION OF DIRECTORS	6
ITEM 2: APPROVAL OF FINANCIAL STATEMENTS AND AUDITORS REPORT	7
ITEM 3: APPOINTMENT OF INDEPENDENT AUDITOR	8
ITEM 4: AMENDMENTS TO DEFINITIONS AND SECTION 7.8 OF BY-LAWS	9
ITEM 5: AMENDMENT TO SECTION 7.5 OF BY-LAWS	10
ITEM 6: AMENDMENT TO SECTION 13 OF BY-LAWS	11
OTHER MATTERS	12
Householding of Proxy Materials	12



**SINOVAC BIOTECH LTD.**

**Executive Offices:  
No. 39 Shangdi Xi Road  
Haidian District, Beijing 100085**

**Registered Office:  
36 Long Street  
City of Saint John  
Antigua and Barbuda**

**NOTICE OF 2010 ANNUAL MEETING OF SHAREHOLDERS**

**TO BE HELD ON JULY 15, 2010**

To the shareholders of Sinovac Biotech Ltd.:

We will hold our 2010 annual meeting of shareholders in Beijing at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People's Republic of China at 9:00 A.M. Beijing time on July 15, 2010, and at the corresponding time in Antigua at No. 6 Temple Street, St. John's, Antigua, for the following purposes:

1. to approve re-election of Weidong Yin, Xianping Wang, Yuk Lam Lo, Simon Anderson and Chup Hung Mok as the Company's directors with a term expiring at the next annual meeting of shareholders and until their successors are duly elected;
2. to approve the audited consolidated financial statements of the Company for the financial year ended December 31, 2009 together with the Report of Independent Registered Public Accounting Firm thereon and the notes thereto;
3. to approve the appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending December 31, 2010 and to authorize the directors of the Company to fix such independent auditor's remuneration;
4. to approve amendments to the definitions and Section 7.8 of the Company's by-laws in order to adopt the definitions used in the International Business Corporations Act of Antigua for "special resolutions" and "ordinary resolutions;"
5. to approve the amendment to Section 7.5 of the Company's by-laws in order to lower the quorum of shareholders' meetings from 50% to 33 1/3 % of common shares outstanding;
6. to approve the amendment to Section 13 of the Company's by-laws in order to change the resolutions required to amend the Company's by-laws to be based on a two-third majority of votes cast, rather than a majority of shares entitled to vote; and

The annual meeting will also transact any other business as may properly come before it or any adjournments or postponements of the annual meeting.



These items of business are described in the attached proxy statement. Only our shareholders of record at the close of business on May 26, 2010, the record date for the annual meeting, are entitled to notice of and to vote at the annual meeting and any adjournments or postponements of the annual meeting.

A list of shareholders eligible to vote at our annual meeting will be available for inspection at the annual meeting, and at our executive offices during regular business hours not later than 10 days after the record date.

**Your vote is very important.** It is important that your shares be represented and voted whether or not you plan to attend the annual meeting in person. You may vote by completing and mailing the enclosed proxy card or voting instruction form. If your shares are held in “street name,” which means shares held of record by a broker, bank or other nominee, you should check the voting instruction form used by that firm to determine whether you will be able to submit your proxy by telephone or over the Internet. Submitting a proxy over the Internet, by telephone or by mailing the enclosed proxy card or voting instruction card will ensure your shares are represented at the annual meeting. Please review the instructions in this proxy statement and the enclosed proxy card or the information forwarded by your broker, bank or other nominee regarding your voting rights.

By Order of the Board of Directors,

/s/ Weidong Yin

---

Weidong Yin  
Chairman, Chief Executive Officer and Secretary

## PROXY STATEMENT

### INFORMATION CONCERNING VOTING AND SOLICITATION

#### General

The enclosed proxy is solicited on behalf of the board of directors of Sinovac Biotech Ltd., a company incorporated in Antigua and Barbuda (“Sinovac,” “we,” “our” or “us”), for use at the 2010 annual meeting of shareholders to be held on July 15, 2010, at 9:00 A.M. Beijing time, or at any continuation, postponement or adjournment thereof, for the purposes discussed in this proxy statement and in the accompanying notice of annual meeting and any business properly brought before the annual meeting. Proxies are solicited to give all shareholders of record an opportunity to vote on matters properly presented at the annual meeting. We intend to mail this proxy statement and accompanying proxy card around June 4, 2010 to all shareholders entitled to vote at the annual meeting. The annual meeting will be held in Beijing at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in Antigua at No. 6 Temple Street, St. John’s, Antigua.

#### Who Can Vote

You are entitled to vote if you were a shareholder of record of our common shares as of the close of business on May 26, 2010. You are entitled to one vote for each common share held on all matters to be voted upon at the annual meeting. Your shares may be voted at the annual meeting only if you are present in person or represented by a valid proxy.

#### Voting by Proxy

The method of voting by proxy differs for shares held as a record holder and shares held in “street name.” If you hold your common shares as a record holder, you may vote by completing, dating and signing the enclosed proxy card and promptly returning it in the enclosed, preaddressed, postage paid envelope or otherwise mailing it to us. If you hold your common shares in “street name,” which means your shares are held of record by a broker, bank or nominee, you will receive instructions from your broker, bank or other nominee that you must follow in order to vote your shares. A large number of banks and brokerage firms are participating in the Broadridge Investor Communication Services online program. This program provides eligible shareholders who receive a paper copy of the Proxy Statement the opportunity to vote via the Internet or by telephone. If your bank or brokerage firm is participating in Broadridge’s program, your voting form will provide instructions. If your voting form does not reference Internet or telephone information, please complete and return the enclosed paper proxy in the self-addressed postage paid envelope provided.

Your vote is very important. Accordingly, please complete, sign and return the enclosed proxy card or voting instruction card whether or not you plan to attend the annual meeting in person. You should vote by submitting your proxy or voting instructions even if you plan to attend the annual meeting.

All properly signed proxies that are received before the polls are closed at the annual meeting and that are not revoked will be voted at the annual meeting according to the instructions indicated on the proxies or, if no direction is indicated, they will be voted “**FOR**” the re-election of each of the directors, “**FOR**” the approval of the audited consolidated financial statements of the Company and Report of Independent Registered Public Accounting Firm thereon, “**FOR**” appointment of the independent auditor, and “**FOR**” the amendments to the Company’s by-laws.

#### Voting in Person

If you are a shareholder of record and plan to attend the annual meeting and wish to vote in person, you will be given a ballot at the annual meeting. Please note, however, that if your shares are held in “street name,” which means your shares are held of record by a broker, bank or other nominee, and you wish to vote in person at the annual meeting, you must bring to the annual meeting a legal proxy from the record holder of the shares (your broker or other nominee) authorizing you to vote at the annual meeting.

## Revocation of Proxy

If you are a shareholder of record, you may revoke your proxy at any time before your proxy is voted at the annual meeting by taking any of the following actions:

- delivering to our corporate secretary a signed written notice of revocation, bearing a date later than the date of the proxy, stating that the proxy is revoked;
- signing and delivering a new proxy, relating to the same shares and bearing a later date than the original proxy; or
- attending the annual meeting and voting in person, although attendance at the annual meeting will not, by itself, revoke a proxy.

Written notices of revocation and other communications with respect to the revocation of proxies should be addressed to:

Sinovac Biotech Ltd.  
No. 39 Shangdi Xi Road,  
Haidian District, Beijing 100085  
People's Republic of China  
Attn: Secretary

If your shares are held in "street name" by a broker or other nominee, you may change your vote by submitting new voting instructions to your broker, bank or other nominee. You must contact your broker, bank or other nominee to find out how to do so.

## Quorum and Votes Required

At the close of business on May 26, 2010, 54,106,261 of our common shares were outstanding and entitled to vote. All votes will be tabulated by the inspector of election appointed for the annual meeting, who will separately tabulate affirmative and negative votes and abstentions.

Shareholders present in person or by proxy representing a majority of our common shares will constitute a quorum at the annual meeting. Common shares held by persons attending the annual meeting but not voting and shares represented by proxies that reflect abstentions as to a particular proposal will be counted as present for purposes of determining a quorum. If a quorum is not present, the annual meeting may be adjourned from time to time until a quorum is established. Section 113(3) of the International Business Corporations Act of Antigua provides that if a quorum is not present within thirty minutes of the time appointed for a meeting of shareholders, the meeting stands adjourned to the same day two weeks thereafter at the same time and place; and, if at the adjourned meeting, a quorum is not present within thirty minutes of the appointed time, the shareholders present constitute a quorum. Because Section 123 of the Amex Company Guide recommends that a quorum of at least 33 1/3% for shareholder meetings, we will not transact business at any adjourned meeting unless shareholders present in person or by proxy at the adjourned meeting represent at least 33 1/3% of our shares.

For Proposal 1, the affirmative vote of a majority of the shares cast is required for the re-election of Weidong Yin, Xianping Wang, Yuk Lam Lo, Simon Anderson and Chup Hung Mok as the Company's directors. Abstentions will not be counted as a vote for the proposal.

For Proposal 2, the affirmative vote of a majority of the shares cast is required for the approval of the audited consolidated financial statements and the Report of Independent Registered Public Accounting Firm. Abstentions will not be counted as a vote for the proposal.

For Proposal 3 , the affirmative vote of a majority of the shares cast is required for the selection of Ernst & Young LLP as our independent auditor and to authorize the board of directors to fix E&Y's remuneration. Abstentions will not be counted as a vote for the proposal.

For Proposal 4 , the affirmative vote of a majority of our common shares outstanding is required for approving the amendments to definitions and Section 7.8 of our by-laws. Abstentions will not be counted as a vote for the proposal.

For Proposal 5 , the affirmative vote of a majority of our common shares outstanding is required for approving the amendment to Section 7.5 of our by-laws. Abstentions will not be counted as a vote for the proposal.

For Proposal 6, the affirmative vote of a majority of our common shares outstanding is required for approving the amendment to Section 13 of our by-laws. Abstentions will not be counted as a vote for the proposal.

### **Solicitation of Proxies**

Our board of directors is soliciting proxies for the annual meeting from our shareholders. We will bear the entire cost of soliciting proxies from our shareholders. In addition to the solicitation of proxies by mail, we will request that brokers, banks and other nominees that hold our common shares, which are beneficially owned by our shareholders, send proxies and proxy materials to those beneficial owners and secure those beneficial owners' voting instructions. We will reimburse those record holders for their reasonable expenses. We may use several of our regular employees, who will not be specially compensated, to solicit proxies from our shareholders, either personally or by telephone, Internet, telegram, facsimile or special delivery letter.

### **Assistance**

If you need assistance in completing your proxy card or have questions regarding the annual meeting, please contact Stephanie Carrington of The Ruth Group, Investor Relations at Tel: +1-646-536-7017 or scarrington@theruthgroup.com, Amy Glynn of The Ruth Group, Investor Relations at Tel: +1-646-246-2262 or aglynn@theruthgroup.com, or Chris Lee of Sinovac Biotech Ltd. at Tel: +86-10-8279-9659, Fax: +86-10-6296-6910 or lill@sinovac.com.

### **Important Information About Us**

Our principal executive offices are located at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People's Republic of China. Our telephone number at this address is +86-10-8289-0088. Investor inquiries should be directed to us at this address and telephone number. Our website is <http://www.sinovac.com> . The information contained on our website is not part of this proxy statement.

## ITEM 1

### RE-ELECTION OF DIRECTORS

The Corporate Governance and Nominating Committee of our board of directors has recommended to the board of director to re-elect Weidong Yin, Xianping Wang, Yuk Lam Lo, Simon Anderson and Chup Hung Mok as the Company's directors at the annual meeting of shareholders until the next annual meeting of shareholders and further directed the management to submit the re-election of directors for approval by the shareholders at the annual meeting.

#### Board Recommendation

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE RE-ELECTION OF ALL OF THE DIRECTORS .**

**ITEM 2**

**APPROVAL OF FINANCIAL STATEMENTS AND AUDITORS REPORT**

Our audited consolidated financial statements for the financial year ended December 31, 2009 together with the Report of Independent Registered Public Accounting Firm thereon and the notes thereto have been provided to our shareholders at the annual meeting of shareholders.

**Board Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE APPROVAL OF OUR AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED DECEMBER 31, 2009 TOGETHER WITH THE REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM THEREON AND THE NOTES THERETO.**

**ITEM 3**

**APPOINTMENT OF INDEPENDENT AUDITOR**

The Audit Committee of our board of directors has selected Ernst & Young LLP (“E&Y”) as our independent auditor for the year ending December 31, 2010, and has further directed that management submit the selection of independent auditor and authorization to the board to fix E&Y’s remuneration for approval by the shareholders at the annual meeting.

**Board Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE APPOINTMENT OF E&Y AS OUR INDEPENDENT AUDITOR FOR FISCAL YEAR 2010 AND TO AUTHORIZE THE BOARD TO FIX E&Y’S REMUNERATION.**

## ITEM 4

### AMENDMENTS TO DEFINITIONS AND SECTION 7.8 OF BY-LAWS

The board of directors proposes that we adopt the definitions used in the International Business Corporations Act of Antigua for “special resolutions” and “ordinary resolutions,” which provide that such resolutions are passed based on a specified majority of votes cast, rather than shares entitled to vote.

The relevant sections in our by-laws currently read as follows:

**ORDINARY RESOLUTION** A resolution passed by a majority of the shares entitled to vote.

#### 7.8 Votes of Shareholders

Subject to any rights or restrictions for the time being attached to any class or classes of shares, every shareholder shall have one vote for each share of which he is the holder. All elections for directors shall be decided by majority vote; all other questions shall be decided by majority vote except as otherwise required by the Act.

We are asking that shareholders representing a majority of our outstanding shares approve a resolution to amend our by-laws by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows:

**ORDINARY RESOLUTION** A resolution passed by a majority of the votes cast by the shareholders who voted in respect of that resolution.

**SPECIAL RESOLUTION** A resolution that is passed by not less than two-thirds of the votes cast by the shareholders who voted in respect of that resolution.

#### 7.8 Votes of Shareholders

Subject to any rights or restrictions for the time being attached to any class or classes of shares, every shareholder shall have one vote for each share of which he is the holder. Unless otherwise required by the Act or these By-Laws, all matters or questions at a shareholders’ meetings shall be decided by ordinary resolutions.

#### Board Recommendation

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” APPROVING THE AMENDMENTS TO DEFINITIONS AND SECTION 7.8 OUR BY-LAWS.**



## ITEM 5

### AMENDMENT TO SECTION 7.5 OF BY-LAWS

To facilitate the holding of shareholders' meetings, the board of directors proposes that the required quorum be lowered from 50% to 33 1/3% of outstanding shares to be in line with the quorum requirements of other listed companies.

The relevant section in our by-laws currently reads as follows:

#### 7.5 Quorum

No business shall be transacted at any shareholders' meeting unless a quorum of shareholders is present at the time when the meeting proceeds to business. Save as is herein otherwise provided, shareholders present in person or by proxy representing a majority of the Corporation's shares shall constitute a quorum.

We are asking that shareholders representing a majority of our outstanding shares approve a resolution to amend our by-laws by replacing Section 7.5 of our by-laws as follows:

#### 7.5 Quorum

No business shall be transacted at any shareholders' meeting unless a quorum of shareholders is present at the time when the meeting proceeds to business. Shareholders present in person or by proxy representing not less than 33 1/3% of the Corporation's shares shall constitute a quorum.

#### **Board Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" APPROVING THE AMENDMENT TO SECTION 7.5 OF OUR BY-LAWS.**

## ITEM 6

### AMENDMENT TO SECTION 13 OF BY-LAWS

The board of directors proposes that we amend our by-laws to provide that any amendments to our by-laws require a special resolution, a resolution passed by a majority of not less than two-thirds of the votes cast by the shareholders who voted in respect of the resolution. Our current by-laws provide that amendments to our by-laws require a vote of shareholders representing a majority of all the shares issued and outstanding.

The relevant section in our by-laws currently reads as follows:

#### 13. Amendments

These By-Laws may be altered, amended or repealed and new By-Laws may be adopted by a vote of the shareholders representing a majority of all the shares issued and outstanding, at any Annual Shareholders' Meeting or at any Special Shareholders' Meeting when the proposed amendment has been set out in the notice of such meeting.

We are asking that shareholders representing a majority of our outstanding shares approve a resolution to amend our by-laws by replacing Section 13 of our by-laws as follows:

#### 13. Amendments

These By-Laws may be altered, amended or repealed and new By-Laws may be adopted by special resolutions.

#### **Board Recommendation**

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" APPROVING THE AMENDMENT TO SECTION 13 OF OUR BY-LAWS.**

## OTHER MATTERS

### Householding of Proxy Materials

The SEC has adopted rules that permit companies and intermediaries (such as banks and brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more shareholders sharing the same address by delivering a single proxy statement addressed to those shareholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for shareholders and cost savings for companies.

This year, a number of banks and brokers with account holders who are our shareholders will be householding our proxy materials. A single proxy statement will be delivered to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders. Once you have received notice from your bank or broker that it will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement and annual report, please notify your bank or broker, direct your request to Stephanie Carrington of The Ruth Group, Investor Relations at Tel: +1-646-536-7017 or scarrington@theruthgroup.com or Amy Glynn of The Ruth Group, Investor Relations at Tel: +1-646-246-2262 or aglynn@theruthgroup.com, or contact Chris Lee of Sinovac Biotech Ltd. at Tel: +86-10-8279-9659, Fax: +86-10-6296-6910 or lill@sinovac.com . Shareholders who currently receive multiple copies of the proxy statement at their address and would like to request householding of their communications should contact their bank or broker.

### **SINOVAC BIOTECH LTD.**

/s/ Weidong Yin

---

Weidong Yin  
Chairman, Chief Executive Officer and Secretary

**SINOVAC BIOTECH LTD.**

( Incorporated in Antigua and Barbuda with limited liability)  
 ( NASDAQ Ticker: SVA)

**FORM OF PROXY FOR 20 10 ANNUAL SHAREHOLDERS MEETING  
 (AND ANY ADJOURNMENT THEREOF)**

I/We, \_\_\_\_\_ of \_\_\_\_\_, being the registered holder of \_\_\_\_\_ common shares <sup>(Note 1)</sup>, par value US\$0.001 per share, of Sinovac Biotech Ltd. (the “Company”) hereby appoint the Chairman of the 20 10 Annual Shareholders Meeting <sup>(Note 2)</sup> or \_\_\_\_\_ of \_\_\_\_\_ as my/our proxy to attend and act for me/us at the 20 10 Annual Shareholders meeting of the Company to be held on July 1 5 , 20 10 at 9:00 A.M. Beijing time in Beijing at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China, and at the corresponding time in Antigua at No. 6 Temple Street, St. John’s, Antigua and at any adjournment thereof, and to vote for me/us as indicated below, or if no such indication is given, as my/our proxy thinks fit.

	<b>RESOLUTION</b>	<b>FOR <sup>(Note 3)</sup></b>	<b>AGAINST <sup>(Note 3)</sup></b>
1.	Re-election of Weidong Yin, Xianping Wang, Yuk Lam Lo, Simon Anderson and Chup Hung Mok as the Company’s directors	<input type="checkbox"/>	<input type="checkbox"/>
2.	Approval of the audited consolidated financial statements for the financial year ended December 31, 2009 together with the Report of Independent Registered Public Accounting Firm thereon and the notes thereto	<input type="checkbox"/>	<input type="checkbox"/>
3.	Appointment of Ernst & Young LLP as independent auditor of the Company for the fiscal year ending December 31, 20 10 and authorization to the directors of the Company to fix such independent auditor’s remuneration	<input type="checkbox"/>	<input type="checkbox"/>
4.	Amendments to definitions and Section 7.8 of the Company’s by-laws	<input type="checkbox"/>	<input type="checkbox"/>
5.	Amendment to Section 7.5 of the Company’s by-laws	<input type="checkbox"/>	<input type="checkbox"/>
6.	Amendment to Section 13 of the Company’s by-laws	<input type="checkbox"/>	<input type="checkbox"/>

Dated \_\_\_\_\_, 2010

Signature(s) <sup>(Note 4)</sup> \_\_\_\_\_

*Notes:*

- 1 Please insert the number of shares registered in your name(s) to which this proxy relates. If no number is inserted, this form of proxy will be deemed to relate to all the shares in the Company registered in your name(s).
- 2 If any proxy other than the Chairman is preferred, strike out the words “ **the Chairman of the Annual General Meeting or** ” and insert the name and address of the proxy desired in the space provided. **ANY ALTERATION MADE TO THIS FORM OF PROXY MUST BE INITIALED BY THE PERSON(S) WHO SIGN(S) IT .**
- 3 **IMPORTANT: IF YOU WISH TO VOTE FOR THE RESOLUTION, TICK THE APPROPRIATE BOX MARKED “FOR.” IF YOU WISH TO VOTE AGAINST THE RESOLUTION, TICK THE APPROPRIATE BOX MARKED “AGAINST.”** Failure to complete any or all the boxes will entitle your proxy to cast his votes at his discretion. **YOUR PROXY WILL ALSO BE ENTITLED TO VOTE AT HIS DISCRETION ON ANY AMENDMENT TO THE RESOLUTIONS REFERRED TO IN THE NOTICE OF ANNUAL GENERAL MEETING OR SUCH OTHER BUSINESS THAT MAY BE COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF.**
- 4 This form of proxy must be signed by you or your attorney duly authorized in writing or, in the case of a corporation, must be either executed under its common seal or under the hand of an officer or attorney or other person duly authorized to sign the same.